Chelsea Therapeutics Logo
FDA Advisory Panel Recommends Approval of Chelsea Therapeutics' NORTHERA(TM) (Droxidopa) for the Treatment of Symptomatic nOH
14 janv. 2014 17h09 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces First Patient Dosed in NORTHERA(TM) (droxidopa) Study 401 for the Treatment of Symptomatic nOH
09 déc. 2013 07h00 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the first patient has been dosed in Study 401, a multi-center,...
Chelsea Therapeutics Logo
Chelsea Therapeutics Completes Public Offering of Common Stock
18 nov. 2013 10h32 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces Pricing of Public Offering of Common Stock
13 nov. 2013 08h44 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces Public Offering of Common Stock
12 nov. 2013 17h49 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Logo
Chelsea Therapeutics Reports Third Quarter 2013 Financial Results
05 nov. 2013 16h22 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the third quarter ended September 30, 2013. "The third...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces FDA Advisory Committee to Review NORTHERA(TM) (droxidopa)
09 oct. 2013 16h01 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that...
Chelsea Therapeutics Logo
Chelsea Therapeutics to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference
19 sept. 2013 07h00 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference at...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces FDA Acceptance of NORTHERA(TM) (droxidopa) NDA Resubmission
04 sept. 2013 16h01 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of...
Chelsea Therapeutics Logo
Chelsea Therapeutics Announces Submission of Additional Information for NORTHERA(TM) (Droxidopa) NDA
14 août 2013 07h00 HE | Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that it has submitted additional information to the U.S. Food and Drug...